Exploration of CRISPR-Cas9 Gene Editing System Utilization for Targeted Induction of Apoptosis in Cancer Cells
DOI:
https://doi.org/10.69855/science.v3i1.436Keywords:
CRISPR-Cas9, Apoptosis, Cancer therapy, Gene editing, DNA damage, Precision oncologyAbstract
The CRISPR-Cas9 gene editing system represents a powerful approach for precision targeting of genetic determinants involved in cancer cell survival. This study evaluated the ability of CRISPR-Cas9 to induce apoptosis in cancer cells through targeted disruption of anti-apoptotic genes. Acute myeloid leukemia (HL-60 and KG-1) and anaplastic thyroid cancer (8505C and C643) cell lines were used to knockout BIRC5 (survivin) and MADD using specific single-guide RNAs. Efficient genome editing was achieved, with indel formation exceeding 50% across all models. Targeting BIRC5 and MADD significantly reduced cell viability to 39.8–54.6% of control levels and induced substantial apoptosis. Total apoptotic populations reached 52.8–60.1% following BIRC5 knockout and 45.3–50.6% following MADD knockout. Apoptosis induction was confirmed by caspase-3/7 activation, increased Sub-G1 accumulation, and cleavage of apoptosis-related proteins, indicating activation of the intrinsic apoptotic pathway.Notably, BIRC5 disruption consistently produced stronger pro-apoptotic effects than MADD across all cancer models. Overall, these findings highlight the therapeutic potential of CRISPR-Cas9–mediated targeting of anti-apoptotic genes as a promising strategy for precision oncology and for overcoming resistance to conventional cancer therapies.
References
Aguirre, A. J., Meyers, R. M., Weir, B. A., Vazquez, F., Zhang, C. Z., Ben-David, U., … Hahn, W. C. (2016). Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discovery, 6(8), 914–929. https://doi.org/10.1158/2159-8290.CD-16-0154
Bakthavachalam, P., Shanmugam, R., & Munirajan, A. K. (2025). CRISPR/Cas9-mediated targeting of MADD suppresses tumor growth and induces apoptosis in anaplastic thyroid carcinoma. Molecular Cancer Therapeutics, 24(2), 315–327.
Fan, Y., Xiong, Y., Li, X., & Guo, W. (2018). CRISPR/Cas9-based functional genomics in cancer research. Cancer Letters, 414, 161–170. https://doi.org/10.1016/j.canlet.2017.11.024
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
Hazafa, A., Rehman, K. U., Jahan, N., & Jabeen, Z. (2020). The role of CRISPR/Cas9 in cancer research: From bench to bedside. Journal of Cellular Physiology, 235(9), 5771–5788. https://doi.org/10.1002/jcp.29417
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821. https://doi.org/10.1126/science.1225829
Kwon, J. H., Kim, J. S., Lee, C., & Kim, H. (2022). Cancer-specific killing using CRISPR/Cas9 via tumor-specific indel targeting (CINDELA). Nature Biotechnology, 40(4), 536–544. https://doi.org/10.1038/s41587-021-01079-4
Li, L., He, Z., Wei, X., Gao, Y., & Chen, Z. (2024). Nanoparticle-mediated delivery of CRISPR/Cas9 for cancer therapy. Advanced Drug Delivery Reviews, 203, 114232. https://doi.org/10.1016/j.addr.2023.114232
Martinez-Lage, M., Torres-Ruiz, R., Puig-Serra, P., Moreno-Gaona, P., Martin, M. C., Moya, F. J., … Ayuso, E. (2020). In vivo CRISPR/Cas9 targeting of oncogenic drivers in cancer. Molecular Therapy, 28(2), 708–719. https://doi.org/10.1016/j.ymthe.2019.11.019
Narimani, M., Sharifi, M., Jalili, A., & Hosseini, A. (2019). CRISPR/Cas9-mediated survivin knockout induces apoptosis and growth inhibition in leukemia cells. Biochemical and Biophysical Research Communications, 509(3), 673–679. https://doi.org/10.1016/j.bbrc.2018.12.093
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., … Peer, D. (2020). CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science Advances, 6(47), eabc9450. https://doi.org/10.1126/sciadv.abc9450
Wang, H. X., Li, M., Lee, C. M., Chakraborty, S., Kim, H. W., Bao, G., & Leong, K. W. (2017). CRISPR/Cas9-based genome editing for disease modeling and therapy. Advanced Drug Delivery Reviews, 121, 114–126. https://doi.org/10.1016/j.addr.2017.08.003
Wang, D., Zhang, F., & Gao, G. (2022). CRISPR-based therapeutic genome editing: Strategies and challenges. Nature Reviews Drug Discovery, 21(3), 193–210. https://doi.org/10.1038/s41573-021-00339-1
Xu, X., Qi, L. S., & Gao, Y. (2019). CRISPR-based technologies for targeted genome engineering in cancer research. Trends in Biotechnology, 37(10), 1052–1066. https://doi.org/10.1016/j.tibtech.2019.03.008
Zhan, T., Rindtorff, N., & Boutros, M. (2017). Wnt signaling in cancer. Oncogene, 36(11), 1461–1473. https://doi.org/10.1038/onc.2016.304
Zhang, Y., Li, S., Yuan, Z., & Liu, J. (2021). Caspase activation and apoptotic signaling pathways in cancer therapy. Cell Death & Disease, 12, 108. https://doi.org/10.1038/s41419-020-03355-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Resti Ariani
This work is licensed under a Creative Commons Attribution 4.0 International License.
